MA48625A - Composés et méthodes de traitement de la douleur viscérale - Google Patents

Composés et méthodes de traitement de la douleur viscérale

Info

Publication number
MA48625A
MA48625A MA048625A MA48625A MA48625A MA 48625 A MA48625 A MA 48625A MA 048625 A MA048625 A MA 048625A MA 48625 A MA48625 A MA 48625A MA 48625 A MA48625 A MA 48625A
Authority
MA
Morocco
Prior art keywords
methods
visceral pain
pain treatment
treatment compounds
compounds
Prior art date
Application number
MA048625A
Other languages
English (en)
French (fr)
Inventor
Cheryl Geraldine Lassen
Marcelo Fabian Piccirillo
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA48625A publication Critical patent/MA48625A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA048625A 2017-05-08 2018-05-08 Composés et méthodes de traitement de la douleur viscérale MA48625A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762503280P 2017-05-08 2017-05-08

Publications (1)

Publication Number Publication Date
MA48625A true MA48625A (fr) 2020-03-18

Family

ID=62245468

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048625A MA48625A (fr) 2017-05-08 2018-05-08 Composés et méthodes de traitement de la douleur viscérale

Country Status (13)

Country Link
US (2) US20200078358A1 (enExample)
EP (1) EP3621619B1 (enExample)
JP (1) JP7247106B2 (enExample)
KR (1) KR20200005614A (enExample)
CN (1) CN110709085A (enExample)
AU (1) AU2018266145A1 (enExample)
BR (1) BR112019023214A2 (enExample)
CA (1) CA3062824A1 (enExample)
EA (1) EA201992638A1 (enExample)
ES (1) ES2956059T3 (enExample)
MA (1) MA48625A (enExample)
MX (2) MX2019013311A (enExample)
WO (1) WO2018208848A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
CA3212135A1 (en) * 2021-03-02 2022-09-09 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists
TW202330496A (zh) * 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法
WO2023150648A2 (en) * 2022-02-02 2023-08-10 Makscientific, Llc Pharmaceutical compositions, and preparation and methods of use thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605906A (en) 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5971080A (en) 1997-11-26 1999-10-26 Central Sprinkler Corporation Quick response dry pipe sprinkler system
US7308894B2 (en) 1998-06-03 2007-12-18 Scott Laboratories, Inc. Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
ATE368037T1 (de) 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
IL150302A (en) 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
NZ580387A (en) 2004-07-12 2011-06-30 Cadila Healthcare Ltd Tricyclic pyrazole derivatives as cannabinoid receptor modulators
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
PL1902034T3 (pl) 2005-06-02 2011-09-30 Glenmark Pharmaceuticals Sa Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
US7597910B2 (en) 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
WO2007035945A1 (en) 2005-09-23 2007-03-29 Janssen Pharmaceutica, N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
ATE459352T1 (de) 2006-07-04 2010-03-15 Janssen Pharmaceutica Nv Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
US7928103B2 (en) 2006-10-17 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
RU2009117203A (ru) 2006-11-03 2010-12-10 Гленмарк Фармасеутикалс С.А. (Ch) Новые лиганды каннабиноидных рецепторов, фармацевтические композиции, содержащие данные лиганды, и способы их получения
WO2008064054A2 (en) 2006-11-21 2008-05-29 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US9763894B2 (en) 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
WO2008079316A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof
EP2120938A4 (en) 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
WO2008119694A1 (en) 2007-03-30 2008-10-09 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
EP2170350B1 (en) 2007-06-21 2013-09-11 Cara Therapeutics, Inc. Substituted imidazoheterocycles
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CA2749884C (en) 2009-01-28 2018-01-23 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
KR20200008045A (ko) 2009-08-28 2020-01-22 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP6043733B2 (ja) 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ， インコーポレイテッド カンナビノイド受容体モジュレーター
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX346533B (es) 2011-02-25 2017-03-14 Arena Pharm Inc Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).
WO2016085941A1 (en) 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
US20180252736A1 (en) 2015-09-01 2018-09-06 Arena Pharmaceuticals, Inc. Cb2 receptor internalization
CN109310673A (zh) 2016-04-10 2019-02-05 艾尼纳制药公司 用选择性cb2受体激动剂治疗的方法
WO2018208847A1 (en) * 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
US12357604B2 (en) * 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
CA3212135A1 (en) * 2021-03-02 2022-09-09 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists
TW202330496A (zh) * 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Also Published As

Publication number Publication date
MX2022008265A (es) 2022-08-04
EP3621619C0 (en) 2023-06-28
JP7247106B2 (ja) 2023-03-28
KR20200005614A (ko) 2020-01-15
CA3062824A1 (en) 2018-11-15
AU2018266145A1 (en) 2019-11-28
JP2020518649A (ja) 2020-06-25
MX2019013311A (es) 2020-08-03
EP3621619B1 (en) 2023-06-28
CN110709085A (zh) 2020-01-17
BR112019023214A2 (pt) 2020-05-26
ES2956059T3 (es) 2023-12-12
WO2018208848A1 (en) 2018-11-15
US20200078358A1 (en) 2020-03-12
US12201633B2 (en) 2025-01-21
EP3621619A1 (en) 2020-03-18
US20230033510A1 (en) 2023-02-02
EA201992638A1 (ru) 2020-03-18

Similar Documents

Publication Publication Date Title
EP3813808A4 (en) Methods of treating substance abuse
MA46102A (fr) Composés de tétracycline et méthodes de traitement
EP3613073A4 (en) DIE TREATMENT
EP3645121A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
EP3370721A4 (en) TREATMENT OF OSTEOARTHRITIS
EP3589659A4 (en) COMPOUNDS AND USES FOR TREATMENT OF CANCER
EP3658139A4 (en) Methods for treating liver diseases
EP3946345A4 (en) METHODS OF TREATMENT OF NEUROPATHIC PAIN
EP3706737A4 (en) ASH11 INHIBITORS AND METHOD OF TREATING THEREOF
EP3448263A4 (en) Electrotherapeutic treatment
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP3630101A4 (en) METHODS OF TREATMENT OF FIBROTIC DISEASES
EP3606531A4 (en) METHOD OF TREATMENT OF CANCER
EP3634422A4 (en) Methods of treating leukodystrophies
EP3745862A4 (en) METHOD OF TREATMENT OF FIBROTIC DISEASES
EP3599983A4 (en) ENDOSCOPES AND TREATMENT PROCEDURES
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
EP3313417A4 (en) METHOD FOR TREATING AUTOIMMUNE AND ALLOIMMUNE DISEASES
EP3383857A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS
IL270900A (en) Treatment of cutaneous disorders
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
EP3852816A4 (en) METHODS OF TREATMENT OF CANCER
MA48625A (fr) Composés et méthodes de traitement de la douleur viscérale
EP3458062A4 (en) Treatment of pain